1-20 of 39
Reinhard Dummer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C048: Intrapatient heterogeneity and targeting microenvironment protection mechanisms in melanoma metastasis

Haley P. Wilson, Glenn L. Mersky, Jelan I. Haj, Jessica L.F. Teh, Phil F. Cheng, Signe Caksa, Manal Mustafa, Isabella Trachtenberg, Francis J. Waltrich, Jr, Casey D. Stefanski, Vivian Chua, Dan A. Erkes, Mitchell P. Levesque, Reinhard Dummer, Timothy J. Purwin, Claudia Capparelli, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2024) 84 (22_Supplement): C048.
https://doi.org/10.1158/1538-7445.TUMBODY-C048
Published: 17 November 2024
View article titled, Abstract C048: Intrapatient heterogeneity and targeting microenvironment protection mechanisms in melanoma metastasis
Journal Articles

Abstract 6942: Single cell resolution of intrapatient drug resistance mechanisms in metastatic melanoma

Haley P. Wilson, Glenn L. Mersky, Jelan I. Haj, Jessica Teh, Phil F. Cheng, Signe Caksa, Casey D. Stefanski, Vivian Chua, Claudia Capparelli, Mitch P. Levesque, Reinhard Dummer, Timothy J. Purwin, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6942.
https://doi.org/10.1158/1538-7445.AM2024-6942
Published: 22 March 2024
View article titled, Abstract 6942: Single cell resolution of intrapatient drug resistance mechanisms in metastatic melanoma
Journal Articles

Abstract 5168: Analysis of biomarker and outcomes data: 7-year update from COLUMBUS

Reinhard Dummer, Keith Flaherty, Shibing Deng, Tao Xie, Phineas Hamilton, Nuzhat Pathan, Caroline Robert, Ana Arance, Jan Willem de Groot, Claus Garbe, Helen J. Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Paolo A. Ascierto, Alessandra di Pietro, Craig B. Davis
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5168.
https://doi.org/10.1158/1538-7445.AM2024-5168
Published: 22 March 2024
View article titled, Abstract 5168: Analysis of biomarker and outcomes data: 7-year update from COLUMBUS
Journal Articles

Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

Reinhard Dummer, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael T. Tetzlaff, Andrew Hill, Jean-Jacques Grob, David C. Portnoy, Celeste Lebbe, Muhammad A. Khattak, Jonathan Cohen, Gil Bar-Sela, Inderjit Mehmi, Ronnie Shapira Frommer, Nicolas Meyer, Yixin Ren, Mizuho Fukunaga-Kalabis, Clemens Krepler, Georgina V. Long
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT002.
https://doi.org/10.1158/1538-7445.AM2023-CT002
Published: 14 April 2023
View article titled, Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
Journal Articles

Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma

Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Antoni Ribas, Ryan J. Sullivan, Timothy Panella, Meredith McKean, Edgardo S. Santos, Jill Clancy, Anna Polli, Alessandra di Pietro, Paolo A. Ascierto
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT069.
https://doi.org/10.1158/1538-7445.AM2023-CT069
Published: 14 April 2023
View article titled, Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma
Journal Articles

Abstract 1301: Evolution of heterogenous BRAFi/MEKi+CDK4/6i resistance mechanisms and targeting site-specific resistant populations in metastatic cutaneous melanoma

Haley P. Wilson, Timothy J. Purwin, Claudia Capparelli, Phil F. Cheng, Mitch P. Levesque, Reinhard Dummer, Jessica Teh, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1301.
https://doi.org/10.1158/1538-7445.AM2023-1301
Published: 04 April 2023
View article titled, Abstract 1301: Evolution of heterogenous BRAFi/MEKi+CDK4/6i resistance mechanisms and targeting site-specific resistant populations in metastatic cutaneous melanoma
Journal Articles

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Ossia M. Eichhoff, Corinne I. Stoffel, Jan Käsler, Luzia Briker, Patrick Turko, Gergely Karsai, Nina Zila, Verena Paulitschke, Phil F. Cheng, Alexander Leitner, Andrea Bileck, Nicola Zamboni, Anja Irmisch, Zsolt Balazs, Aizhan Tastanova, Susana Pascoal, Pål Johansen, Rebekka Wegmann, Julien Mena, Alaa Othman, Vasanthi S. Viswanathan, Judith Wenzina, Andrea Aloia, Annalisa Saltari, Andreas Dzung, TuPro Consortium, Michael Krauthammer, Stuart L. Schreiber, Thorsten Hornemann, Martin Distel, Berend Snijder, Reinhard Dummer, Mitchell P. Levesque
Journal: Cancer Research
Cancer Res (2023) 83 (7): 1128–1146.
https://doi.org/10.1158/0008-5472.CAN-22-1826
Published: 04 April 2023
View article titled, ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Open the PDF for ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract 1035: Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma

Ryan Sullivan, Laura Collins, Manuel Rodrigues, Paul Nathan, Jessica C. Hassel, Reinhard Dummer, John Kirkwood, Piotr Rutkowski, Jean-Francois Baurain, Marcus O. Butler, Max Schlaak, Sebastian Ochsenreither, Shaad E. Abdullah, Chris Holland, Koustubh Ranade, Alexander N. Shoushtari
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1035.
https://doi.org/10.1158/1538-7445.AM2023-1035
Published: 04 April 2023
View article titled, Abstract 1035: Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma
Journal Articles

Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study

Reinhard Dummer, Nuzhat Pathan, Zhou Zhu, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Michelle Edwards, Jean Cantey-Kiser, Alessandra di Pietro, Shibing Deng, Paolo A. Ascierto, Keith Flaherty
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 6403.
https://doi.org/10.1158/1538-7445.AM2022-6403
Published: 15 June 2022
View article titled, Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study
Journal Articles

Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression

Annalisa Saltari, Andreas Dzung, Marika Quadri, Natascia Tiso, Nicola Facchinello, Alberto Hernández-Barranco, Susana Garcia-Silva, Laura Nogués, Corinne Isabelle Stoffel, Phil F. Cheng, Patrick Turko, Ossia M. Eichhoff, Francesca Truzzi, Alessandra Marconi, Carlo Pincelli, Héctor Peinado, Reinhard Dummer, Mitchell P. Levesque
Journal: Cancer Research
Cancer Res (2021) 81 (23): 6044–6057.
https://doi.org/10.1158/0008-5472.CAN-21-0117
Published: 01 December 2021
View article titled, Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression
Open the PDF for Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression in another window
Includes: Supplementary data
Journal Articles

Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma

Sophie Piperno-Neumann, Jessica C. Hassel, Piotr Rutkowski, Jean-Francois Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Paul Nathan
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT002.
https://doi.org/10.1158/1538-7445.AM2021-CT002
Published: 01 July 2021
View article titled, Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma
Journal Articles

Abstract A22: Effects of CDK4/6/MAPK targeting combinations on melanoma and the tumor immune microenvironment

Jessica L.F. Teh, Phil F. Cheng, Dan E. Erkes, Timothy J. Purwin, Conroy Field, Connor Hollingworth, Julio Aguirre-Ghiso, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2020) 80 (19_Supplement): A22.
https://doi.org/10.1158/1538-7445.MEL2019-A22
Published: 02 October 2020
View article titled, Abstract A22: Effects of CDK4/6/MAPK targeting combinations on melanoma and the tumor immune microenvironment
Journal Articles

Abstract 2161: Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cell exclusion in tumors and resistance to anti-PD-1 treatment

Jorg Wischhusen, Kilian Wistuba-Hamprecht, Patrick N. Harter, Phil Cheng, Alexander Martens, Falk Gogolla, Yumi Nonomura, Paula Romer, Sven D. Koch, Markus Haake, Christine Schuberth-Wagner, Manfred Rudiger, Eugen Leo, Michael Mittelbronn, Mitchell P. Levesque, Hubert Hackl, Reinhard Dummer, Benjamin Weide
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 2161.
https://doi.org/10.1158/1538-7445.AM2020-2161
Published: 15 August 2020
View article titled, Abstract 2161: Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cell exclusion in tumors and resistance to anti-PD-1 treatment
Journal Articles

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Caroline Robert, Reinhard Dummer, Ana Arance, Antoni Ribas, Jeffrey Weber, Georgina V. Long, John Haanen, Paul Nathan, Paolo A. Ascierto, Eduard Gasal, Anthony D'Amelio, Severine Bettinger, Aislyn D. Boran, Dirk Schadendorf
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT120.
https://doi.org/10.1158/1538-7445.AM2019-CT120
Published: 01 July 2019
View article titled, Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)
Journal Articles

Abstract 2304: In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms

Jessica Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Ines Keibler, HooKim Kim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2304.
https://doi.org/10.1158/1538-7445.AM2018-2304
Published: 01 July 2018
View article titled, Abstract 2304: In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms
Journal Articles

Abstract 5329: Telomerase reverse transcriptase promoter methylation in metastatic melanoma

Sumit Borah, Seung J. Lee, Yiping Fan, Raymond L. Barnhill, Reinhard Dummer, John M. Kirkwood, Armita Bahrami
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5329.
https://doi.org/10.1158/1538-7445.AM2018-5329
Published: 01 July 2018
View article titled, Abstract 5329: <em>Telomerase reverse transcriptase</em> promoter methylation in metastatic melanoma
Journal Articles

Abstract 566: High dimensional single cell analysis predicts response to anti-PD-1 immunotherapy

Carsten Krieg, Malgorzata Nowicka, Silvia Guglietta, Sabrina Schindler, Felix J. Hartmann, Lukas M. Weber, Reinhard Dummer, Mark D. Robinson, Mitchell P. Levesque, Burkhard Becher
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 566.
https://doi.org/10.1158/1538-7445.AM2018-566
Published: 01 July 2018
View article titled, Abstract 566: High dimensional single cell analysis predicts response to anti-PD-1 immunotherapy
Journal Articles

Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i

Reinhard Dummer, Dirk Schadendorf, Paul Nathan, Hussein Tawbi, Caroline Robert, Paolo A. Ascierto, Antoni Ribas, Celeste Lebbé, Mario Mandala, Naoya Yamazaki, Erika Richtig, Wilson H. Miller, Eduard Gasal, Mathilde Kaper, Jan C. Brase, Bijoyesh Mookerjee, Georgina V. Long
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT182.
https://doi.org/10.1158/1538-7445.AM2018-CT182
Published: 01 July 2018
View article titled, Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced <em>BRAF</em> V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i
Journal Articles

Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)

James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, John Haanen, Michele Maio, Grant McArthur, Dana Walker, Linda Rollin, Christine Horak, F. Stephen Hodi, Jedd D. Wolchok
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT075.
https://doi.org/10.1158/1538-7445.AM2017-CT075
Published: 01 July 2017
View article titled, Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)
Journal Articles

Abstract 300: Inhibition of oncogenic MAPK signaling in melanoma triggers SOX2-dependent adaptive drug resistance

Stefanie Flueckiger, Andrea Aloia, Lukas Frischknecht, Amanda Tuozzo, Davide Croci, Olga Shakhova, Christian Britschgi, Reinhard Dummer, Mitchell Paul Levesque, Wilhelm Krek
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 300.
https://doi.org/10.1158/1538-7445.AM2016-300
Published: 15 July 2016
View article titled, Abstract 300: Inhibition of oncogenic MAPK signaling in melanoma triggers SOX2-dependent adaptive drug resistance